Prentice H G, Blacklock H A, Janossy G, Gilmore M J, Price-Jones L, Tidman N, Trejdosiewicz L K, Skeggs D B, Panjwani D, Ball S
Lancet. 1984 Mar 3;1(8375):472-6. doi: 10.1016/s0140-6736(84)92848-4.
For more than 15 years preclinical studies have suggested that acute graft-versus-host disease (aGvHD) might be prevented by the removal of immunocompetent T lymphocytes from the donor marrow inoculum. To test this observation in man 14 patients were given marrows virtually (greater than 99%) depleted of identifiable donor marrow T lymphocytes by the use of a "cocktail" of specific anti-T-cell monoclonal antibodies (MBG6 and RFT8) and rabbit complement. Patients were not given immunosuppressive prophylaxis after bone-marrow transplantation. Moderate to severe (grades II-IV) GvHD was totally prevented. 2 of 13 evaluable patients showed mild (grade I) skin GvHD only. Although peripheral blood recovery was slower than that obtained with other forms of GvHD prophylaxis, no fatal infections occurred. All patients survived the early post-transplant period.
15年多来,临床前研究表明,通过从供体骨髓接种物中去除具有免疫活性的T淋巴细胞,或许可以预防急性移植物抗宿主病(aGvHD)。为了在人体中验证这一观察结果,14名患者接受了使用特异性抗T细胞单克隆抗体(MBG6和RFT8)及兔补体的“鸡尾酒”疗法,使其骨髓中可识别的供体骨髓T淋巴细胞几乎完全清除(超过99%)。骨髓移植后,患者未接受免疫抑制预防治疗。中重度(II-IV级)移植物抗宿主病得到了完全预防。13名可评估患者中有2名仅出现了轻度(I级)皮肤移植物抗宿主病。尽管外周血恢复比其他形式的移植物抗宿主病预防方法要慢,但未发生致命感染。所有患者均度过了移植后的早期阶段。